Drug intelligence / Profile preview

ME001

Development stage: Preclinical
Lead developer: Beijing Zhidao Biological Technology
Modality: Peptides

Overview

ME001 is a peptide-based therapeutic being developed by Letolab for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It functions as an agonist of the glucagon-like peptide-1 (GLP-1) receptor and targets an additional, undisclosed biological pathway. This dual-targeting approach is intended to provide synergistic metabolic benefits, addressing both weight reduction and the underlying liver pathology associated with NASH. The drug is currently in the IND-enabling stage of development.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on ME001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME001.

Explore the full profile